Novel ADC Extends PFS in HER2-Low Breast Cancer

https://www.medscape.com/viewarticle/novel-adc-extends-pfs-her2-low-breast-cancer-2026a100146i?ecd=mkm_ret_261108_mscpmrk_onc_breast-cancer_mai_etid8874665&uac=148436CN&impID=8874665 The HER2-targeted antibody-drug conjugate (ADC) trastuzumab rezetecan more than doubled progression-free survival compared with standard chemotherapy in patients with HER2-low advanced breast cancer in the phase 3 HORIZON-Breast06 trial.